Hepatitis C Infection (Chronic Liver Disease)
Overview
Plain-Language Overview
Chronic Hepatitis C Infection is a viral illness that primarily affects the liver, an essential organ responsible for filtering toxins and producing important proteins. This infection is caused by the Hepatitis C virus (HCV), which can lead to long-term liver inflammation and damage. Over time, the liver may develop scarring (fibrosis) and eventually severe scarring called cirrhosis, which impairs its function. Many people with this condition may not have symptoms initially, but it can cause fatigue, jaundice, and abdominal discomfort as it progresses. Chronic infection increases the risk of serious complications like liver failure and liver cancer. The disease is transmitted mainly through blood exposure, such as sharing needles or unscreened blood transfusions.
Clinical Definition
Chronic Hepatitis C Infection is defined as persistent infection with the Hepatitis C virus (HCV) lasting more than six months, characterized by ongoing hepatocellular inflammation and progressive liver injury. The virus is a single-stranded RNA virus of the Flaviviridae family that primarily infects hepatocytes, leading to immune-mediated liver damage. Chronic infection results in fibrosis and can progress to cirrhosis, portal hypertension, and hepatocellular carcinoma. The disease is a major cause of chronic liver disease worldwide and a leading indication for liver transplantation. Diagnosis relies on detection of HCV RNA and serologic markers. The natural history varies, with some patients remaining asymptomatic for decades while others develop rapid progression to end-stage liver disease.
Inciting Event
Exposure to contaminated blood via intravenous drug use or transfusion initiates infection.
Percutaneous exposure such as needlestick injury or unsafe medical procedures triggers viral entry.
Vertical transmission from infected mother to newborn can occur but is less common.
Sexual transmission through mucosal contact with infected blood or body fluids is a less frequent trigger.
Latency Period
The incubation period ranges from 2 weeks to 6 months before seroconversion.
Chronic infection is established when viremia persists beyond 6 months.
Symptoms of chronic liver disease may not appear for decades after initial infection.
Progression to cirrhosis typically occurs over 20-30 years in untreated patients.
Diagnostic Delay
Many patients are asymptomatic during early chronic infection, delaying diagnosis.
Non-specific symptoms like fatigue and mild hepatomegaly are often attributed to other causes.
Lack of routine screening in high-risk populations leads to missed early detection.
Elevated liver enzymes may be intermittent, causing under-recognition of ongoing liver injury.
Clinical Presentation
Signs & Symptoms
Fatigue is the most common symptom in chronic hepatitis C infection.
Right upper quadrant discomfort or dull pain may occur due to liver inflammation.
Jaundice appears in advanced liver disease or acute exacerbations.
Pruritus can result from cholestasis in chronic liver disease.
Easy bruising and bleeding may develop due to impaired hepatic synthesis of clotting factors.
History of Present Illness
Patients often report fatigue, malaise, and vague abdominal discomfort over months to years.
Signs of chronic liver disease such as jaundice, ascites, or encephalopathy appear late.
Some patients experience intermittent episodes of right upper quadrant pain due to liver inflammation.
Extrahepatic manifestations like arthralgia or cryoglobulinemia may precede liver symptoms.
Past Medical History
History of intravenous drug use or blood transfusions before 1992 is common.
Previous diagnosis of acute hepatitis or unexplained elevated liver enzymes may be present.
Coexisting HIV infection or other chronic liver diseases can worsen prognosis.
Prior alcohol use disorder exacerbates liver injury and fibrosis progression.
Family History
No direct hereditary pattern exists, but familial clustering may occur due to shared risk behaviors.
Family members may have hepatitis C infection from shared exposure to contaminated needles or blood.
Genetic polymorphisms affecting immune response can influence disease progression but are not well defined.
No known inherited syndromes directly cause hepatitis C infection.
Physical Exam Findings
Hepatomegaly with or without tenderness is common in chronic hepatitis C infection.
Jaundice may be present in advanced liver disease due to impaired bilirubin metabolism.
Spider angiomas and palmar erythema indicate chronic liver dysfunction and portal hypertension.
Ascites and caput medusae suggest progression to cirrhosis with portal hypertension.
Gynecomastia and testicular atrophy can be seen in advanced liver disease due to hormonal imbalance.
Diagnostic Workup
Diagnostic Criteria
Diagnosis of chronic hepatitis C requires detection of anti-HCV antibodies by serologic testing followed by confirmation with HCV RNA PCR to demonstrate active viral replication. Chronic infection is established when HCV RNA remains detectable for more than six months. Liver function tests often show elevated alanine aminotransferase (ALT) levels, but these can fluctuate. Liver biopsy or noninvasive fibrosis assessment tools may be used to evaluate the degree of liver damage. Genotyping of HCV is important for guiding antiviral therapy.
Pathophysiology
Key Mechanisms
Chronic hepatocyte infection by Hepatitis C virus leads to persistent immune-mediated liver inflammation.
Cytotoxic T cell response causes hepatocyte injury and promotes fibrosis through activation of hepatic stellate cells.
Viral RNA replication within hepatocytes sustains chronic infection and evades immune clearance.
Progressive fibrosis and cirrhosis result from ongoing liver injury and extracellular matrix deposition.
Immune evasion mechanisms of the virus, including high mutation rate, allow persistence and chronicity.
| Involvement | Details |
|---|---|
| Organs | Liver is the primary organ affected by chronic hepatitis C infection, resulting in inflammation, fibrosis, cirrhosis, and risk of hepatocellular carcinoma. |
| Tissues | Liver parenchyma undergoes chronic inflammation and fibrosis in hepatitis C infection, leading to cirrhosis. |
Fibrotic tissue replaces normal liver architecture during disease progression, impairing liver function. | |
| Cells | Hepatocytes are the primary cells infected by hepatitis C virus, leading to chronic inflammation and liver injury. |
Kupffer cells act as liver-resident macrophages that mediate immune response and inflammation in chronic hepatitis C. | |
T lymphocytes (CD8+ cytotoxic T cells) target infected hepatocytes but can contribute to liver tissue damage. | |
| Chemical Mediators | Interferon-gamma is produced by activated T cells and promotes antiviral immune responses in hepatitis C infection. |
Tumor necrosis factor-alpha (TNF-α) mediates inflammation and hepatocyte apoptosis contributing to liver injury. | |
Transforming growth factor-beta (TGF-β) promotes hepatic fibrosis by activating stellate cells. |
Treatments
Pharmacological Treatments
Sofosbuvir
- Mechanism:
Inhibits the NS5B RNA-dependent RNA polymerase, preventing viral RNA replication.
- Side effects:
Fatigue
Headache
Anemia
- Clinical role:
First-line
Ledipasvir
- Mechanism:
Inhibits the NS5A protein, disrupting viral replication and assembly.
- Side effects:
Fatigue
Headache
Nausea
- Clinical role:
First-line
Glecaprevir
- Mechanism:
Inhibits the NS3/4A protease, blocking viral polyprotein processing.
- Side effects:
Elevated liver enzymes
Fatigue
Headache
- Clinical role:
First-line
Pibrentasvir
- Mechanism:
Inhibits the NS5A protein, essential for viral replication and assembly.
- Side effects:
Fatigue
Headache
Nausea
- Clinical role:
First-line
Ribavirin
- Mechanism:
Nucleoside analog that inhibits viral RNA synthesis and induces lethal mutagenesis.
- Side effects:
Hemolytic anemia
Teratogenicity
Fatigue
- Clinical role:
Adjunctive
Non-pharmacological Treatments
Avoidance of alcohol to reduce progression of liver fibrosis and cirrhosis.
Regular monitoring with liver function tests and imaging to assess for hepatocellular carcinoma.
Liver transplantation in cases of end-stage liver disease or hepatocellular carcinoma.
Prevention
Pharmacological Prevention
Direct-acting antivirals (DAAs) effectively eradicate HCV and prevent disease progression.
Hepatitis B vaccination is recommended to prevent coinfection in susceptible patients.
Antiviral therapy reduces risk of hepatocellular carcinoma by preventing cirrhosis.
Prophylactic beta-blockers may be used to prevent variceal bleeding in cirrhosis.
Non-pharmacological Prevention
Avoidance of intravenous drug use reduces risk of HCV transmission.
Safe sex practices decrease sexual transmission of hepatitis C.
Screening of blood products has dramatically reduced transfusion-related HCV infection.
Regular monitoring with liver ultrasound and alpha-fetoprotein aids early detection of hepatocellular carcinoma.
Alcohol abstinence slows fibrosis progression and improves outcomes.
Outcome & Complications
Complications
Cirrhosis leading to portal hypertension and liver failure is a major complication.
Hepatocellular carcinoma (HCC) risk is significantly increased in chronic hepatitis C.
Hepatic encephalopathy results from liver dysfunction and toxin accumulation.
Esophageal variceal bleeding occurs due to portal hypertension in cirrhosis.
Mixed cryoglobulinemia syndrome can cause vasculitis and renal impairment.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Hepatitis C Infection (Chronic Liver Disease) versus Hepatitis B Virus Infection
Hepatitis C Infection (Chronic Liver Disease) | Hepatitis B Virus Infection |
|---|---|
Exposure to blood transfusions, intravenous drug use, or high-risk sexual behavior | Exposure to blood or body fluids in endemic areas or vertical transmission |
Positive hepatitis C antibody and detectable HCV RNA by PCR | Positive hepatitis B surface antigen (HBsAg) and hepatitis B DNA |
Usually causes chronic infection with slow progression to cirrhosis | Can cause acute hepatitis with possible fulminant liver failure or chronic infection |
Hepatitis C Infection (Chronic Liver Disease) versus Alcoholic Liver Disease
Hepatitis C Infection (Chronic Liver Disease) | Alcoholic Liver Disease |
|---|---|
No significant alcohol use, risk factors for viral hepatitis | History of chronic heavy alcohol consumption |
Elevated ALT > AST, often with positive HCV RNA | Elevated AST > ALT with AST:ALT ratio > 2 |
Lymphoid aggregates and portal inflammation with interface hepatitis | Mallory bodies and steatosis on liver biopsy |
Hepatitis C Infection (Chronic Liver Disease) versus Nonalcoholic Fatty Liver Disease (NAFLD)
Hepatitis C Infection (Chronic Liver Disease) | Nonalcoholic Fatty Liver Disease (NAFLD) |
|---|---|
Associated with bloodborne viral exposure or intravenous drug use | Associated with obesity, diabetes, and metabolic syndrome |
Elevated ALT and positive HCV RNA | Mildly elevated transaminases with ALT often > AST |
No steatosis; may show signs of chronic hepatitis or cirrhosis | Ultrasound shows hepatic steatosis without focal lesions |
Hepatitis C Infection (Chronic Liver Disease) versus Autoimmune Hepatitis
Hepatitis C Infection (Chronic Liver Disease) | Autoimmune Hepatitis |
|---|---|
Negative autoimmune markers, positive HCV antibody and RNA | Positive antinuclear antibody (ANA) and anti-smooth muscle antibody |
Normal or mildly elevated immunoglobulins | Elevated IgG levels |
Portal lymphoid aggregates with mild interface hepatitis | Interface hepatitis with plasma cell infiltration |
Hepatitis C Infection (Chronic Liver Disease) versus Primary Biliary Cholangitis
Hepatitis C Infection (Chronic Liver Disease) | Primary Biliary Cholangitis |
|---|---|
Negative AMA, positive HCV RNA | Positive antimitochondrial antibody (AMA) |
Elevated transaminases with normal or mildly elevated alkaline phosphatase | Elevated alkaline phosphatase and gamma-glutamyl transferase |
Portal inflammation without bile duct destruction | Destruction of intrahepatic bile ducts with granulomas |